Neel K. Krishna, Ph.D.

‌ ‌

Professor

Department of Microbiology and Molecular Cell Biology

Lewis Hall, Room 3184
700 W. Olney Road
Norfolk, Virginia 23508
Office: (757) 446- 5677
Lab: (757) 446- 5645
Email: krishnnk@evms.edu

My Bibliography (NCBI)

Dr. Krishna’s profile on Google Scholar

LinkedIn

ORCiD


Education

  • PhD, Pennsylvania State University School of Medicine, Hershey, PA
  • Postdoctoral Fellow, The Scripps Research Institute, La Jolla, CA

Professional Positions

2017 – Present

  • Professor
    Eastern Virginia Medical School
    Department of Microbiology & Molecular Cell Biology
    Department of Pediatrics

2011 – 2017

  • Associate Professor
    Eastern Virginia Medical School
    Department of Microbiology & Molecular Cell Biology
    Department of Pediatrics

2003 – 2011

  • Assistant Professor
    Eastern Virginia Medical School
    Department of Microbiology & Molecular Cell Biology
    Department of Pediatrics

‌Research Interests

Keywords:  peptide, inhibitor, complement, Peptide Inhibitor of Complement C1 (PIC1), anti-inflammatory.

Discovery of PIC1

My laboratory, in collaboration with Dr. Kenji Cunnion's research group in the EVMS Department of Pediatrics, has developed a novel family of peptides that inhibit the complement system, an innate immune defence mechanism in vertebrates. These molecules are termed Peptide Inhibitor of Complement C1 (PIC1). Research in our laboratories currently focuses on determining the mechanism whereby PIC1 inhibits complement activation as well as evaluating the anti-inflammatory potential of PIC1 in various pre-clinical models of disease such as acute hemolytic transfusion reaction (AHTR) and hypoxic ischemic encephalopathy (HIE). The HIE work is in collaboration with Dr. Tushar's research group in the Department of Pediatrics. We have recently demonstrated that PIC1 can also inhibit myeloperoxidase activity, a significant source of inflammation in a variety of inflammatory conditions and possesses anti-microbial activity.

Therapeutic Development of PIC1

PIC1 is a unique synthetic peptide platform with multiple mechanisms of action and likely therapeutic value for many autoimmune and inflammatory diseases that currently do not have a viable, safe clinical intervention. We are currently in the process of evaluating PIC1 in different pre-clinical models with the long term goal of therapeutic utilization of this technology in humans.


Patents

United States Patent 8,906,845

United States Patent 8,241,843

11 Foreign patents

17 Provisional Patents (foreign and domestic)